Gwalia Healthcare is a manufacturer and supplier of pharmaceutical grade containers and closures. The companies' medical device division manufactures components and assembles devices.
Dynamic Extractions is a spin out company of Brunel University (now based in Tredegar) which was set up to commercialise Hydrodynamic Counter Current Chromatography (HdCCC) technology developed by the Brunel Institute of Bioengineering (BIB). The technology has potential application in high throughput screening for drug discovery and process development in large scale commercial use.
ReNeuron have developed an exosome technology platform that offers a delivery mechanism for a variety of potential payloads that could include siRNA, mRNA, proteins, small molecules and genes to a defined cell type in a selected tissue. The company are now seeking partnerships with companies developing promising drug candidates that may benefit from using this platform
BioMonde is a multinational pharmaceutical and wound care company. The company currently specialises in the manufacture and distribution of larval debridement therapy (also known as maggot therapy) products for use in chronic and hard to heal wounds. The company manufactures and distributes its products across the UK and Europe from its production facilities in Bridgend, UK and Hamburg, Germany.
TrakCel have developed OCELLOS, a software platform for supply chain management for advanced cell and gene therapy. The platform is suited for therapies both in clinical trial and commercial settings. TrakCel have also launched a consultancy service to share their expertise in cell and gene therapy process development
St Mary’s Pharmaceutical Unit (SMPU) is a MHRA licenced and regulated pharmaceutical specials manufacturer and provide a range of medicines and pharmaceutical services for patients and customers worldwide. SMPU develops novel patient treatments from an initial concept, or formulations for a special clinical need such as a new procedure or for patient safety.
Neurochase is a Cardiff-based start-up that have developed a drug delivery system for the delivery of therapies into the central nervous system using Convection Enhanced Delivery, including cell and gene therapies.
Biodexa Pharmaceuticals was formed by the 2022 merger of Cardiff-based Midatech Pharma and US-based Bioasis. Midatech specialised in developing technologies for the improved delivery of drugs, whilst Bioasis were developing drugs to treat central nervous system disorders. Biodexa has combines these two technologies to develop a pipeline of products aimed at primary and metastatic cancers of the brain. The company’s lead product is currently being assessed in clinical trials.
MeOmics is a Cardiff University spin-out company who have created a physiological assay for psychiatric diseases using a combination of artificial intelligence and stem cells to predict a patient's response to a drug therapy. This platform has application in drug discovery as a preclinical screening assay, and may have future application in diseases diagnosis and personalised medicine.
Heor is an independent consultancy specialising in health economics modelling, outcomes research, statistical analysis, market access and value communication.
